scholarly journals Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma

2012 ◽  
Vol 3 (6) ◽  
pp. 931-936 ◽  
Author(s):  
TAKAHIRO EINAMA ◽  
SHIGETO UEDA ◽  
HITOSHI TSUDA ◽  
KAZUHIRO OGASAWARA ◽  
KAZUO HATSUSE ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Growth Factor Receptor ◽  
Ductal Adenocarcinoma ◽  
Cytoplasmic Expression ◽  
Epidermal Growth

Epidermal growth factor receptor as a therapeutic target against pancreatic ductal adenocarcinoma

Pancreatology ◽  
2015 ◽  
Vol 15 (3) ◽  
pp. S27
Author(s):  
Teresa Blasco Lazaro ◽  
Pierfrancesco Vargiu ◽  
Sagrario Ortega ◽  
Carmen Guerra ◽  
Mariano Barbacid
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Therapeutic Target ◽  
Growth Factor Receptor ◽  
Ductal Adenocarcinoma ◽  
Epidermal Growth

scholarly journals NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer

2020 ◽  
Vol 9 (8) ◽  
pp. 2390 ◽  
Author(s):  
Shazia Bano ◽  
Girgis Obaid ◽  
Joseph W. R. Swain ◽  
Marina Yamada ◽  
Brian W. Pogue ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Cancer Therapeutics ◽  
Ductal Adenocarcinoma ◽  
Multiple Tumor ◽  
Her 2 ◽  
Epidermal Growth

Receptor heterogeneity in cancer is a major limitation of molecular targeting for cancer therapeutics. Single-receptor-targeted treatment exerts selection pressures that result in treatment escape for low-receptor-expressing tumor subpopulations. To overcome this potential for heterogeneity-driven resistance to molecular targeted photodynamic therapy (PDT), we present for the first time a triple-receptor-targeted photoimmuno-nanoconjugate (TR-PIN) platform. TR-PIN functionalization with cetuximab, holo-transferrin, and trastuzumab conferred specificity for epidermal growth factor receptor (EGFR), transferrin receptor (TfR), and human epidermal growth factor receptor 2 (HER-2), respectively. The TR-PINs exhibited up to a 24-fold improvement in cancer cell binding compared with EGFR-specific cetuximab-targeted PINs (Cet-PINs) in low-EGFR-expressing cell lines. Photodestruction using TR-PINs was significantly higher than the monotargeted Cet-PINs in heterocellular 3D in vitro models of heterogeneous pancreatic ductal adenocarcinoma (PDAC; MIA PaCa-2 cells) and heterogeneous head and neck squamous cell carcinoma (HNSCC, SCC9 cells) containing low-EGFR-expressing T47D (high TfR) or SKOV-3 (high HER-2) cells. Through their capacity for multiple tumor target recognition, TR-PINs can serve as a unique and amenable platform for the effective photodynamic eradication of diverse tumor subpopulations in heterogeneous cancers to mitigate escape for more complete and durable treatment responses.

Sign in / Sign up

Export Citation Format

Share Document